Abstract
Backgroud: Tsutsugamushi disease was really uncommon in the pediatric clinical. However, it can be quite severe, those who suffer them Tsutsugamushi disease can progress to multiple organ dysfunction syndrome (MODS) and hemophagocytic syndrome (HPS). Unfortunately, there were few reports on pulmonary hemorrhage caused by tsutsugamushi disease, especially in children. Because of the nonspecific clinical presentations, it was difficult to differentiate from other diseases. The mortality would be up to 60% if inappropriate antibiotics were used.
Case Presentation: We report a three-year-old girl infected with tsutsugamushi, which manifested as MODS, HPS and diffuse alveolar hemorrhage. After administation of chloromycetin, the patient’s temperature fell down to normal 2 days later and mechanical ventilation was stopped after 1 week. The patient was discharged after three weeks of treatment. Since the typical eschar of tsutsugamushi disease is mostly concealed, misdiagnosis and delay in treatment often cause severe complications.
Conclusion: Chloromycetin may be an alternative antibiotic choice of treatment for severe pediatric tsutsugamushi disease, though it has toxic effects on bone marrow hematopoietic function.
Keywords: Chloromycetin, pediatric, pulmonary hemorrhage, tsutsugamushi.
Current Signal Transduction Therapy
Title:Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin
Volume: 10 Issue: 1
Author(s): Yafeng Liang, Linxia Wang, Xiaojiao Ye, Min Wang, Chunxue Yan and Guoquan Pan
Affiliation:
Keywords: Chloromycetin, pediatric, pulmonary hemorrhage, tsutsugamushi.
Abstract: Backgroud: Tsutsugamushi disease was really uncommon in the pediatric clinical. However, it can be quite severe, those who suffer them Tsutsugamushi disease can progress to multiple organ dysfunction syndrome (MODS) and hemophagocytic syndrome (HPS). Unfortunately, there were few reports on pulmonary hemorrhage caused by tsutsugamushi disease, especially in children. Because of the nonspecific clinical presentations, it was difficult to differentiate from other diseases. The mortality would be up to 60% if inappropriate antibiotics were used.
Case Presentation: We report a three-year-old girl infected with tsutsugamushi, which manifested as MODS, HPS and diffuse alveolar hemorrhage. After administation of chloromycetin, the patient’s temperature fell down to normal 2 days later and mechanical ventilation was stopped after 1 week. The patient was discharged after three weeks of treatment. Since the typical eschar of tsutsugamushi disease is mostly concealed, misdiagnosis and delay in treatment often cause severe complications.
Conclusion: Chloromycetin may be an alternative antibiotic choice of treatment for severe pediatric tsutsugamushi disease, though it has toxic effects on bone marrow hematopoietic function.
Export Options
About this article
Cite this article as:
Liang Yafeng, Wang Linxia, Ye Xiaojiao, Wang Min, Yan Chunxue and Pan Guoquan, Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311001316
DOI https://dx.doi.org/10.2174/1574362410666150311001316 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Current Advances in Clinical Trials for Rare Disease Populations: Spotlight on the Patient
Current Reviews in Clinical and Experimental Pharmacology Studies on Novel Pyridine and 2-pyridone Derivatives of N-arylpiperazine as α-adrenoceptor Ligands
Medicinal Chemistry Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology A UPLC-MS/MS Method for Simultaneous Determination of Six Bioactive Compounds in Rat Plasma, and its Application to Pharmacokinetic Studies of Naoshuantong Granule in Rats
Current Pharmaceutical Analysis Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Sarcoidosis and Sarcoid Reactions in Endometrial Cancer Cases Masquerading Advanced Stage Malignancy
Current Women`s Health Reviews Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Transitional Connective Tissue Diseases: Description of Four Cases
Current Rheumatology Reviews A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Radiological Diagnosis of Renal Thrombosis in Children
Current Pediatric Reviews Granulomatosis with Polyangiitis (GPA) in a 15-year-old Girl with Facial Acne-like Ulcers: A Case Report
Infectious Disorders - Drug Targets The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer
Protein & Peptide Letters Neutrophil MiRNA-128-3p is Decreased During Active Phase of Granulomatosis with Polyangiitis
Current Genomics Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Cefpodoxime Proxetil-Related Hemolysis and Acute Interstitial Nephritis
Current Drug Safety